Portfolio
2
companies
Exscientia
Exscientia builds artificial intelligence platforms to design and discover new medicines.
ONI
ONI develops desktop super-resolution microscopes for cellular and molecular research.
Shaun Rodriguez
Director of Life Science Research
Shaun directs life science research at Casdin Capital, following previous analytical roles at Cowen and Company.
LinkedInThe Oxford biotech spinout secured $75m to expand international operations and scale its microscopy platform.
"ONI’s technology democratises cutting-edge science, enabling researchers to develop new angles to explore and understand the complexity of biological systems at super-resolution,"
The financing was led by SoftBank Vision Fund 2 with participation from Novo Holdings and Blackrock to expand the proprietary drug pipeline.
"We believe Exscientia’s innovative use of AI to discover and design better quality drugs with greater efficiency has the potential to create important medicines faster than ever before. With the convergence of technology and biology, drug discovery is rapidly evolving in ways that will reshape the industry. The Exscientia team have been leaders in AI-based drug discovery since the field’s inception and we believe they will continue shaping its future."
